Your Health Questions
Answered by Professionals

There are several reasons your brain can resist mood disorder management, including slow-to-shift brain chemistry, depressive thinking patterns, low energy, stress or trauma, and the need for treatment adjustments and consistency. There are several factors to consider; see below for practical next steps like reassessing your plan with a clinician, starting smaller, protecting sleep, reducing isolation, and knowing urgent warning signs that need immediate care, plus more details that could change which steps you take in your healthcare journey.

Circadian rhythm disruption is a leading, underrecognized cause of ongoing bipolar mood swings; aligning sleep timing, light exposure, and daily routines can lower relapse risk and improve stability. Evidence-based next steps include IPSRT, strict sleep protection with a fixed wake time, carefully supervised light therapy, evening blue-light reduction, medication timing review, and plans for travel and seasonal shifts, with clear guidance on when to seek urgent care. There are several factors to consider that can change your next steps; see below for key details and safety considerations.

Depression biomarkers are measurable signals in your body, including inflammation markers like CRP and IL-6, cortisol and other stress measures, BDNF, neurotransmitters, gut patterns, and related labs such as thyroid or hormone panels, that can explain persistent symptoms when standard care falls short and point to more precise, personalized treatment, even though no single test can diagnose depression yet. There are several factors to consider. See below for the specific biomarkers to discuss with your clinician, how they can guide medication and therapy choices, the urgent red flags that need immediate care, and practical next steps you can start now.

If standard Crohn’s treatments have failed, experimental options through clinical trials may be a critical next step, offering access to newer biologics, targeted oral small molecules, stem cell and microbiome therapies, and personalized approaches under rigorous safety monitoring. There are several factors to consider. See below to understand more, including how to confirm active inflammation first, who qualifies, potential benefits and risks, key questions to ask your gastroenterologist, when to seek urgent care, and supportive tools to help plan next steps.

Fecal transplant trials are a research based next step for IBS when diet changes, fiber, probiotics, medications, and stress management have not helped, targeting the gut microbiome; early studies show some people improve, often those with IBS-D, though results are mixed and participation within trials is safer than unregulated clinics. There are several factors to consider; see below to understand who might be a candidate, how trials are done and monitored, potential risks and red flag symptoms to rule out other diseases, and which standard treatments to try or optimize before enrolling.

The real difference between IBD studies is whether your treatment changes: observational studies track your usual care with low risk, while interventional trials test new therapies with closer monitoring, potential benefit, and added risks such as possible placebo. There are several factors to consider that can shape your next step, including current symptom control, risk comfort, and personal goals; flaring patients may be better matched to interventional options, while stable patients who want to help research with minimal risk may prefer observational. For critical details, safety red flags, and the questions to ask your doctor, see below.

Persistent IBS symptoms may reflect incomplete testing, gut brain miscommunication, microbiome imbalance, hidden food triggers, or subtle inflammation that suggests IBD rather than IBS. There are several factors to consider; see below to understand more and to learn which red flags require urgent care. New IBD specialist protocols use precise diagnostics and early, personalized treatment plans, including advanced medications, gut directed therapies, targeted probiotic and diet strategies, and structured follow up, and the complete details below can help you decide when to search for an IBD specialist near me and what to do next.

Still suffering with Crohn’s disease or ulcerative colitis despite treatment? Mayo Clinic’s IBD clinical trials provide research-backed access to emerging biologics, oral small molecules, microbiome approaches, and precision strategies with close specialist monitoring, though suitability depends on your diagnosis, disease activity, and prior medication response. There are several factors to consider. See below to understand more about eligibility, safety and placebo use, potential benefits and risks, urgent warning signs, and concrete next steps for discussing enrollment with your gastroenterologist.

New long-term data show that modern Crohn’s drugs are generally safe over years, with serious side effects uncommon; infections are a manageable risk with screening and vaccines, anti-TNFs carry a small lymphoma signal especially with thiopurines, and gut selective options like vedolizumab plus IL-12/23 and IL-23 agents have reassuring profiles while reducing hospitalizations, surgery, and steroid exposure. There are several factors to consider before choosing or adjusting therapy, including age, prior infections or cancer, pregnancy plans, and use of combination immunosuppression. See below for drug-by-drug risks, who needs extra caution, and when to call your doctor so you can decide your next steps confidently.

There are several factors to consider. Newer, more selective oral JAK inhibitors like upadacitinib, filgotinib, and the TYK2 agent deucravacitinib can provide strong symptom relief with potentially fewer side effects than earlier JAKs, but risks remain and depend on age, cardiovascular and clotting risks, infection risk, and cancer history. Next steps include confirming your diagnosis and disease activity, reviewing vaccines and baseline labs, and discussing with your rheumatologist whether a newer JAK inhibitor, a different biologic, or combination therapy fits your risk profile and goals; see the complete guidance below for key cautions, monitoring needs, and questions to ask that could change your plan.

IBD gene therapy is an emerging, research-stage approach that targets the root genetic and immune drivers of Crohn’s disease and ulcerative colitis to reduce inflammation more precisely than standard drugs, using methods like anti-inflammatory gene delivery, RNA-based silencing, and engineered microbiome therapies. It is not yet standard care, and benefits, risks, and eligibility differ by patient and trial, but it may offer longer-lasting relief for those not responding to current treatments. There are several factors to consider; see the complete details below to guide next steps with your gastroenterologist, from clinical trial options and genetic testing to red flags that need urgent care.

The latest FDA approved drugs for IBD in 2026 give people with Crohn’s disease and ulcerative colitis more precise options, including IL-23 inhibitors, next-generation JAK inhibitors, S1P modulators, and emerging dual-targeted approaches that can raise remission rates, cut steroid use, and add convenient oral choices. There are several factors to consider, so talk with your gastroenterologist about fit based on disease severity, prior drug response, safety risks, and practical issues like pregnancy or insurance, and see the complete details below for which option to ask about, how to prepare for your visit, and urgent symptoms that need immediate care.

If you’re still struggling with Crohn’s disease or ulcerative colitis, Mount Sinai IBD research recruitment may offer access to emerging therapies, close expert monitoring, and a chance to contribute to future care, with some study costs often covered. There are several factors to consider, including eligibility, risks such as side effects or placebo, and how participation fits with your current treatment, so talk with your gastroenterologist. See below for key details on who qualifies, what to expect, safety oversight, potential costs, and when to seek urgent care.

New IL-12/23 inhibitors in the pipeline may be a breakthrough for people still struggling with psoriasis, psoriatic arthritis, or IBD, offering more precise targeting, longer-lasting responses with fewer injections, and higher skin clearance even after prior biologic failure. There are several factors to consider, including how these compare with IL-23 only options and which patient profiles may benefit most. Safety and next steps matter, such as infection risks, TB screening, vaccination review, symptom tracking, and asking about clinical trials or switching therapies with your clinician. See the complete answer below for key details that could change your next steps.

Perianal Crohn’s trials offer regulated, medically guided next steps when standard treatments are not enough, giving access to advanced biologics and innovative options like stem cell approaches with expert oversight while helping drive future approvals. There are several factors to consider, including eligibility, safety safeguards, how a study may work with your current meds, and when to seek urgent care. See below for the complete details, key questions for your doctors, and practical next steps that can shape your care plan.

There are several factors to consider. Severe IBD treatments can fail for multiple reasons, including primary nonresponse, loss of response from low drug levels or antibodies, incorrect or overlapping diagnoses, structural complications that medication cannot reverse, and adherence or lifestyle triggers. Next clinical steps include objective testing and therapeutic drug monitoring, switching or combining therapies with a treat to target plan, advanced imaging, timely surgical consultation, and exploring clinical trials; see below for key nuances, red flag symptoms, and decision points that could change your next move.

There are several factors to consider: IBD is an autoimmune misfire that can keep inflaming the gut despite treatment, and 30 to 40 percent of people do not reach durable remission on first-line therapies due to loss of response, side effects, or aggressive disease; see below to understand more. Clinical trials can provide access to advanced options and close monitoring but carry real risks, including no benefit or placebo, disease worsening, unknown side effects, medication restrictions, and a heavy visit burden; see the complete guidance below on trial phase, rescue plans, cost coverage, alternatives, and warning signs that may require urgent care and a doctor discussion.

There are several factors to consider; see below to understand more. Persistent symptoms despite optimized mesalamine and steroids may reflect inadequate rectal drug reach, undertreatment or adherence issues, steroid dependence, disease extension, or infection, and next steps include objective reassessment plus escalation to advanced therapies such as biologics (anti-TNF, vedolizumab, ustekinumab), oral small molecules (JAK inhibitors, ozanimod), and consideration of investigational options or clinical trials.

There are several factors to consider if you are still symptomatic on infliximab; see below to understand more, including target trough ranges and urgent red flags. A common, fixable cause is low infliximab trough levels due to rapid clearance from active inflammation, anti-drug antibodies, or under-dosing, which therapeutic drug monitoring can confirm. Next steps often include increasing the dose, shortening infusion intervals, adding an immunomodulator, or switching therapies, while checking for noninflammatory causes if levels are adequate.

There are several factors to consider: ongoing instability in Bipolar 1 vs Bipolar 2 often reflects missed diagnosis or subtype, suboptimal medication choice or dosing and poor adherence, sleep disruption, substance use, or untreated co‑occurring conditions. See below to understand more. Effective next steps include confirming the correct subtype, optimizing mood stabilizers before antidepressants, adding structured psychotherapy, tracking sleep and mood, and addressing lifestyle and advanced options with a specialist; see below for the key differences by subtype and urgent warning signs that change what to do next.

Bipolar mood tracking apps in 2026 can help, but stability depends on new clinical protocols that convert data into care. Key standards include guideline-aligned symptom monitoring, personalized relapse signatures, integrated safety plans with crisis pathways, physician-integrated dashboards, medication adherence tracking with context, detection of mixed states and rapid cycling, and ethical, transparent AI. There are several factors to consider for your next steps. See below for the complete guidance on how to evaluate apps, when to escalate to a clinician, and which details could change your treatment plan.

New phase 3 fast-acting antidepressants aim to deliver relief in days or hours by targeting glutamate and GABA and enhancing neuroplasticity, with phase 3 candidates joined by already approved rapid options like esketamine and zuranolone, and psilocybin-assisted therapy advancing in late trials. They may help people with treatment-resistant or severe depression, and postpartum depression, but can require supervised dosing and have important safety considerations. There are several factors to consider. See below to understand more, including candidacy, side effects, monitoring needs, clinical trial access, and the questions to ask your doctor that could shape your next steps.

There are several factors to consider: standard antidepressants that act on serotonin and norepinephrine often take 4 to 8 weeks because the brain must slowly recalibrate, and some people do not respond due to differences in biology, genetics, inflammation, or neuroplasticity. Auvelity, an oral combination of dextromethorphan and bupropion that modulates glutamate and boosts dopamine and norepinephrine, may bring earlier relief for some in about one week but has specific side effects, interactions, and eligibility concerns; see below to understand more and for critical details that could shape your next steps with your clinician.

Bipolar depression often resists standard antidepressants because it is biologically distinct from major depression, and using antidepressants alone can sometimes worsen symptoms by triggering mania, rapid cycling, or mixed states; see below for how sleep disruption, missed mixed features, substance use, medical conditions, and dosing or duration issues can all drive nonresponse. Research-backed next steps include mood stabilizers like lithium and lamotrigine, specific atypical antipsychotics, evidence-based psychotherapy and circadian rhythm care, and when needed advanced options such as ketamine or ECT, with guidance on when to re-evaluate the diagnosis and metabolic or inflammatory contributors found below.

Stubborn foot fungus usually persists because treatment is stopped too early, your shoes or environment keep re-seeding the skin, the diagnosis is incorrect, the nails are involved, or an underlying issue like diabetes or poor circulation is present. Use a proven OTC antifungal like terbinafine for 2 to 4 weeks while keeping feet and shoes very dry and disinfected, know that nail infections often need prescription or oral medicines, and see a clinician if there is no improvement in 2 to 4 weeks or urgently for spreading redness, pain, pus, fever, or if you have diabetes or immune problems. There are several factors and step by step details that can change your next move; see below for the complete guidance.

There are several factors to consider. See below to understand more. On a third biologic, loss of response often means antibodies or low drug levels, targeting the wrong pathway, or symptoms not from active IBD; next steps are therapeutic drug monitoring, objective inflammation tests, and ruling out infection before switching to a new mechanism like anti-integrin, IL-23, or JAK therapy, with combo therapy or clinical trials considered and urgent red flags, lifestyle, and mental health factors listed below.

If you have tried three antidepressants with no relief, this may meet criteria for treatment-resistant depression, but it is still very treatable. There are several factors to consider, including ruling out bipolar disorder and medical contributors, and proven options like dose optimization, augmentation, switching classes, ketamine or esketamine, TMS or ECT, and structured psychotherapy; see below for details that can guide which next steps are right for you and when to seek urgent help.

For some people, newer oral targeted drugs like JAK inhibitors (tofacitinib, baricitinib, upadacitinib) can replace biologic infusions for RA, psoriatic arthritis, ulcerative colitis, and related conditions, offering pill convenience with effectiveness similar to certain biologics. These pills are not for everyone and carry FDA boxed warnings for serious infections, blood clots, heart events, and some cancers, so the medically approved next steps are to review your disease control, discuss personal risks such as age, smoking, and clot or heart history, and confirm required monitoring with your specialist. There are several factors to consider; see below for complete details and decision guides that could change the safest plan for you.

There are several factors to consider. When current therapy is failing, you may qualify for a Crohn’s drug study if you have a confirmed diagnosis, moderate to severe active disease despite prior treatments, and proper documentation for screening, while active infection, recent surgery, certain cancers, or pregnancy often exclude people. New protocols are testing targeted biologics, JAK inhibitors, S1P modulators, and microbiome or stem cell therapies, and the benefits, risks, and step-by-step enrollment process could shape your next steps. See the complete eligibility details, safety considerations, and how to begin with your GI, records, and screening below.

There are several factors to consider. DBS is not first-line or an emergency treatment and is often investigational for depression; it is explored for severe, treatment-resistant depression after failure of at least four adequately dosed medications from different classes, evidence-based psychotherapy, and often ECT, with some programs also requiring TMS, followed by detailed medical, neurological, and cognitive screening and a multidisciplinary review. See below for the new, step-by-step eligibility process, who may not qualify, key risks and expected outcomes, and how to talk with your psychiatrist about referrals and clinical trials, since important details could change your next steps.